diabetestalk.net

Diabetes And Hypertension: A Position Statement By The American Diabetes Association

2017 Position Statement From The American Diabetes Association (ada) On Hypertension In Diabetes

2017 Position Statement From The American Diabetes Association (ada) On Hypertension In Diabetes

2017 Position Statement from the American Diabetes Association (ADA) on Hypertension in Diabetes Patients with diabetes often have numerous comorbid conditions such as obesity, heart disease, kidney disease and hypertension to name a few. Hypertension or high blood pressure (BP), in particular, can lead to increased risks for atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) and attendant microvascular complications. The last time the ADA provided a position statement on hypertension was more than 15 years ago. Given the increasing rise in the numbers of people afflicted by diabetes, increased BMI and obesity, it is timely that this body has revised its statement on hypertension in this patient population. Predominantly focusing on Type 2 Diabetes (T2D), the position statement can be summarized as follows: Regular monitoring of BP in the office and in the home Careful assessment and implementation of all antihypertensive medications and supplements particularly in patients with known kidney disease or clinical proteinuria (300 mg albumin/g creatinine) A BP goal for all diabetics of <140/90 mm Hg based on clinical evidence With individualization of targets if <130/80 mm Hg based on severity of CV risk and The position statement also describes in detail how BP should be taken at every clinic visit, with repeated measurements to confirm the diagnosis of hypertension, the use of home BP measurement to confirm the elevations that may be seen during the clinic visit, and the importance of checking for orthostatic hypotension at the initial hypertension visit and periodically thereafter. This highlights the importance of autonomic instability in diabetes. Overall, this document is an important read for the practitioner who cares for patients with diabetes and Continue reading >>

Us Hypertension In Diabetes Position Statement Released

Us Hypertension In Diabetes Position Statement Released

US hypertension in diabetes position statement released A position statement based on hypertension and diabetes has been released in the US. The document , which was last updated in 2003, was written by nine leading diabetes experts on behalf of the American Diabetes Association (ADA). The update incorporates findings from recent, noteworthy BP trials, including ACCORD, ADVANCE, SPRINTT and the Hypertension Optimal Treatment (HOT) trial. A newly added pictorial algorithm for the treatment of confirmed hypertension in people with diabetes has also been included. Speaking to Endocrine Today,George Bakris,professor of medicine and director of the American Society of Hypertension (ASH) and the Comprehensive Hypertension Center at University of Chicago Medicine and a co-author of the statement, said: There are a number of new findings in this position paper.There is a recommendation to check standing BP on initial visits among people with diabetes to assess both autonomic function as well as potential volume depletion. While there is a strong position for a BP of less than 140/90 mm Hg, there is a clear recommendation for a BP of less than 130/80 mm Hg once the patient understands they are at high CV risk. Subsequent analyses from a long-term follow-up of ACCORD (ACCORDIAN) and multiple meta-analyses in thousands of patients suggest that a BP of less than 140 mm Hg clearly shows a significant reduction in CVD events and a slowed progression of nephropathy. Professor Bakris aded: Those who achieve a BP of less than 130 mm Hg show a further, albeit smaller, reduction in CVD events, but not renal events. Lifestyle management plans for lowering BP have also been highlighted in the guideline and include suggestions on weight loss, nutrition and increased physical activity. The s Continue reading >>

Ada Updates Position Statement On Hypertension In Diabetes

Ada Updates Position Statement On Hypertension In Diabetes

ADA updates position statement on hypertension in diabetes For most patients with diabetes and hypertension, a combination of in-clinic and home-based blood pressure monitoring, a BP target of less than 140/90 mm Hg, individualized antihypertensive treatment and lifestyle modification are key to reduce the risk for atherosclerotic cardiovascular disease, heart failure and microvascular complications, according to a new position statement released by the American Diabetes Association. The statement, written by nine leading diabetes experts on behalf of the ADA, updates the latest advances in care since the association last published a statement on the topic in 2003. The update incorporates findings from recent, noteworthy BP trials, including ACCORD, ADVANCE, SPRINT and the Hypertension Optimal Treatment (HOT) trial, and includes a newly added pictorial algorithm for the treatment of confirmed hypertension in patients with diabetes. There are a number of new findings in this position paper, George Bakris, MD, professor of medicine and director of the ASH Comprehensive Hypertension Center at University of Chicago Medicine and a co-author of the statement, told Endocrine Today. There is a recommendation to check standing BP on initial visits among people with diabetes to assess both autonomic function as well as potential volume depletion. While there is a strong position for a BP of less than 140/90 mm Hg, there is a clear recommendation for a BP of less than 130/80 mm Hg once the patient understands they are at high CV risk. Subsequent analyses from a long-term follow-up of ACCORD (ACCORDIAN) and multiple meta-analyses in thousands of patients suggest that a BP of less than 140 mm Hg clearly shows a significant reduction in CVD events and a slowed progression of nephrop Continue reading >>

New Ada Hypertension And Diabetes Treatment Guide Features Visual Aid

New Ada Hypertension And Diabetes Treatment Guide Features Visual Aid

New ADA hypertension and diabetes treatment guide features visual aid Clinicians can consult a diagram to plan treatment of hypertension in diabetes patients as part of the new American Diabetes Association guidelines. Diabetes and Hypertension: A Position Statement by the American Diabetes Association was published in the September 2017 issue of Diabetes Care, and online on Aug. 22. The statement updates the ADAs previous statement on hypertension and diabetes published in 2003. Numerous studies have shown that antihypertensive therapy reduces ASCVD [atherosclerotic cardiovascular disease] events, heart failure, and microvascular complications in people with diabetes, wrote Ian H. de Boer, MD , of the University of Washington, Seattle, and his colleagues. The statement is a collaboration between nine diabetes experts from the United States, Europe, and Australia whose specialties include endocrinology, nephrology, cardiology, and internal medicine ( Diabetes Care. 2017 Sep.;40:1273-84 ). The statement recommends that diabetes patients have their blood pressure checked at every routine clinical visit and that those with an elevated blood pressure on a clinical visit (defined as office-based measurements of 140/90 mm Hg and higher) have multiple measurements, including on a separate day to confirm the diagnosis. In addition, during the initial evaluation, and then periodically, diabetes patients should be assessed for orthostatic hypotension to individualize blood pressure goals, select the most appropriate antihypertensive agents, and minimize adverse effects of antihypertensive therapy, according to the recommendations. For most patients with diabetes and hypertension, the goal should be a blood pressure below 140/90 mm Hg, and even lower targets may be appropriate fo Continue reading >>

Aace Algorithm Offers New Guidance On Managing T2dm

Aace Algorithm Offers New Guidance On Managing T2dm

AACE Algorithm Offers New Guidance on Managing T2DM How Does It Compare With ADA/EASD Guidelines? This feature requires the newest version of Flash. You can download it here . Position Statements vs Algorithms for Type 2 Diabetes Hi. I am Dr. Anne Peters from the University of Southern California. Today I will take on the difficult task of comparing the American Association of Clinical Endocrinologists (AACE) algorithms for the treatment of type 2 diabetes[ 1 ] with the position statement of the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) for the management of hyperglycemia in type 2 diabetes.[ 2 ] In fairness, I will disclose that I was one of the authors of the ADA/EASD position statement. I have biases, but I also know the process by which algorithms are created. Thus, I have some insider information to use when evaluating these statements. Furthermore, it is difficult to compare them while using the terms "algorithm," "position statement," and "guidelines" correctly. The ADA/EASD document is a position statement, which means that it is not meant to be an algorithm or a guideline. The AACE document is a series of algorithms with very minimal text; it delineates the treatment of all elements of type 2 diabetes, (hyperglycemia, obesity, prediabetes, hypertension, and dyslipidemia). The ADA/EASD position statement looks only at the treatment of hyperglycemia in type 2 diabetes. I will focus first on that position statement and then I will discuss the AACE algorithms. Continue reading >>

Pardon Our Interruption...

Pardon Our Interruption...

As you were browsing www.mdlinx.com something about your browser made us think you were a bot. There are a few reasons this might happen: You're a power user moving through this website with super-human speed. You've disabled JavaScript in your web browser. A third-party browser plugin, such as Ghostery or NoScript, is preventing JavaScript from running. Additional information is available in this support article. To request an unblock, please fill out the form below and we will review it as soon as possible. You reached this page when attempting to access from 35.193.228.56 on 2018-01-13 00:53:11 UTC. Trace: c8ebef03-e724-4af0-8698-a34607f7cd5f via 0894b646-a920-4bbe-adae-63c4b22043a0 Continue reading >>

Ada Issues Updated Position Statement On Hypertension And Diabetes

Ada Issues Updated Position Statement On Hypertension And Diabetes

ACP Diabetes Monthly | From ACP Internist Weekly | September 8, 2017 ADA issues updated position statement on hypertension and diabetes The statement updates the American Diabetes Association's 2003 position statement on this topic and summarizes clinical trials of intensive hypertension treatment strategies. The American Diabetes Association (ADA) recently issued an updated position statement on diagnosis and treatment of hypertension in patients with diabetes. The position statement, which updates the ADA's 2003 position statement on this topic, will appear in the September Diabetes Care and was published online on Aug. 22. It was developed by nine diabetes experts and summarizes clinical trials of intensive hypertension treatment strategies , such as the ACCORD BP (Action to Control Cardiovascular Risk in Diabetes-Blood Pressure) trial, the ADVANCEBP (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled EvaluationBlood Pressure) trial, the HOT (Hypertension Optimal Treatment) trial, and SPRINT (Systolic Blood Pressure Intervention Trial). The resulting recommendations include the following: Blood pressure should be measured at every routine clinical care visit in people with diabetes. If blood pressure is found to be 140/90 mm Hg or higher, it should be confirmed with multiple readings, including on a different day (B recommendation). All hypertensive patients with diabetes should have home blood pressure monitored to identify white-coat hypertension (B recommendation). The treatment goal for most patients with diabetes and hypertension should be below 140 mm Hg systolic and below 90 mm Hg diastolic (A recommendation). For patients at high risk for cardiovascular disease, lower targets, such as below 130/80 mm Hg, may be appropriate if they Continue reading >>

Diabetes And Hypertension: A Position Statement By The American Diabetes Association

Diabetes And Hypertension: A Position Statement By The American Diabetes Association

Hypertension is common among patients with diabetes, with the prevalence depending on type and duration of diabetes, age, sex, race/ethnicity, BMI, history of glycemic control, and the presence of kidney disease, among other factors (1–3). Furthermore, hypertension is a strong risk factor for atherosclerotic cardiovascular disease (ASCVD), heart failure, and microvascular complications. ASCVD—defined as acute coronary syndrome, myocardial infarction (MI), angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin—is the leading cause of morbidity and mortality for individuals with diabetes and is the largest contributor to the direct and indirect costs of diabetes. Numerous studies have shown that antihypertensive therapy reduces ASCVD events, heart failure, and microvascular complications in people with diabetes (4–8). Large benefits are seen when multiple risk factors are addressed simultaneously (9). There is evidence that ASCVD morbidity and mortality have decreased for people with diabetes since 1990 (10,11) likely due in large part to improvements in blood pressure control (12–14). This Position Statement is intended to update the assessment and treatment of hypertension among people with diabetes, including advances in care since the American Diabetes Association (ADA) last published a Position Statement on this topic in 2003 (3). DEFINITIONS, SCREENING, AND DIAGNOSIS Blood pressure should be measured at every routine clinical care visit. Patients found to have an elevated blood pressure (≥140/90 mmHg) should have blood pressure confirmed using multiple readings, including measurements on a separate day, to diagnose hypertension. B All hypertensive pa Continue reading >>

Diabetic Retinopathy: A Position Statement By The American Diabetes Association

Diabetic Retinopathy: A Position Statement By The American Diabetes Association

Diabetic retinopathy diagnostic assessment and treatment options have improved dramatically since the 2002 American Diabetes Association Position Statement (1). These improvements include the widespread adoption of optical coherence tomography to assess retinal thickness and intraretinal pathology and wide-field fundus photography to reveal clinically silent microvascular lesions. Treatment of diabetic macular edema is now achieved by intravitreous injection of antivascular endothelial growth factor agents, and the same drugs are now used for proliferative diabetic retinopathy. Improvements in medications and devices for the systemic therapy of diabetes have also improved the ability of patients to optimize their metabolic control. This Position Statement incorporates these recent developments for the use of physicians and patients.Diabetic retinopathy is a highly specific neurovascular complication of both type 1 and type 2 diabetes, the prevalence of which strongly correlates to both the duration of diabetes and level of glycemic control. A pooled meta-analysis involving 35 studies conducted worldwide from 1980 to 2008 estimated global prevalence of any diabetic retinopathy and proliferative diabetic retinopathy (PDR) among patients to be 35.4% and 7.5%, respectively (2). Diabetic retinopathy is the most frequent cause of new cases of blindness among adults aged 2074 years in developed countries. Glaucoma, cataracts, and other disorders of the eye occur earlier and more frequently in people with diabetes.In addition to diabetes duration, factors that increase the risk of or are associated with retinopathy include chronic hyperglycemia (3,4), nephropathy (5), hypertension (6), and dyslipidemia (7). Intensive diabetes management with the goal of achieving near-normogly Continue reading >>

Review Of The Ada Standards Of Medical Care In Diabetes 2018 | Annals Of Internal Medicine | American College Of Physicians

Review Of The Ada Standards Of Medical Care In Diabetes 2018 | Annals Of Internal Medicine | American College Of Physicians

Author, Article, and Disclosure Information This article was published at Annals.org on 3 April 2018. St. Mark's Hospital and St. Mark's Diabetes Center, Salt Lake City, Utah (J.J.C.) UND School of Medicine and Health Sciences, Grand Forks, North Dakota (E.L.J.) Touro University College of Osteopathic Medicine, Vallejo, California (J.H.S.) Utah State University, Taylorsville, Utah (L.P.) Acknowledgment: The authors thank Sarah Bradley; Matt Petersen; and Erika Gebel Berg, PhD, for their invaluable assistance in the reviewing and editing of this manuscript. The full Standards of Medical Care in Diabetes2018 was developed by the ADA's Professional Practice Committee: Rita R. Kalyani, MD, MHS (Chair); Christopher Cannon, MD; Andrea L. Cherrington, MD, MPH; Donald R. Coustan, MD; Ian de Boer, MD, MS; Hope Feldman, CRNP, FNP-BC; Judith Fradkin, MD; David Maahs, MD, PhD; Melinda Maryniuk, Med, RD, CDE; Medha N. Munshi, MD; Joshua J. Neumiller, PharmD, CDE; and Guillermo E. Umpierrez. ADA staff support includes Erika Gebel Berg, PhD; Tamara Darsow, PhD; Matt Petersen; Sacha Uelmen, RDN, CDE; and William T. Cefalu, MD. Disclosures: Dr. Chamberlain reports other support from Novo Nordisk, Sanofi Aventis, Janssen, and Merck outside the submitted work. Dr. Johnson reports personal fees from Novo Nordisk, Medtronic, and Sanofi outside the submitted work. Dr. Rhinehart reports employment with and stock ownership in Glytec. Dr. Shubrook reports personal fees from Novo Nordisk, Lilly Diabetes, and Intarcia outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-0222 . Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that he Continue reading >>

Managing Hypertension In Diabetes: A Position Statement From The Ada

Managing Hypertension In Diabetes: A Position Statement From The Ada

Managing hypertension in diabetes: a position statement from the ADA Managing hypertension in diabetes: a position statement from the ADA The ADA has released a position statement to update the assessment and treatment of hypertension among patients with diabetes. The American Diabetes Association (ADA) has released a position statement to update the assessment and treatment of hypertension among patients with diabetes. The position statement, published in Diabetes Care, includes advances in care since the ADA last published a statement on this topic in 2003. The ADA notes that antihypertensive therapy is shown to reduce atherosclerotic cardiovascular disease (ASCVD) events, heart failure, and microvascular complications in patients with diabetes. There have also been reductions in ASCVD morbidity and mortality in patients with diabetes since 1990, which are likely due to improvements in blood pressure control. Treatment should be individualized to the specific patient based on their comorbidities; their anticipated benefit for reduction in ASCVD, heart failure, progressive diabetic kidney disease, and retinopathy events; and their risk of adverse events, according to the ADA. This conversation should be part of a shared decision-making process between the clinician and the individual patient. The ADA has made the following recommendations: Clinicians should measure blood pressure at every routine clinical care visit. Patients with elevated blood pressure 140/90 mmHg should have blood pressure confirmed with multiple readings to diagnose hypertension (Grade B recommendation). Hypertensive patients with diabetes should have home blood pressure monitoring to identify white-coat hypertension (Grade B recommendation). Orthostatic measurement of blood pressure should be per Continue reading >>

Ada Position Statement On Diabetes, Hypertension

Ada Position Statement On Diabetes, Hypertension

ADA Position Statement on Diabetes, Hypertension The American Diabetes Association has released a position statement on diabetes and hypertension. These are the strongest-graded recommendations: Most patients with diabetes and hypertension should be treated to a systolic blood pressure goal of <140 mmHg and a diastolic blood pressure goal of <90 mmHg. Patients with blood pressure 140/90 mmHg should have timely titration of pharmacologic therapy added to lifestyle therapy. Patients with BP 160/100 mmHg should have prompt initiation and timely titration of 2 drugs or a single-pill combination of drugs to reduce cardiovascular (CV) events. Treatment for hypertension should include drug classes demonstrated to reduce CV events in patients with diabetes: ACE inhibitors, angiotensin receptor blockers (ARBs), thiazide-like diuretics, or dihydropyridine calcium channel blockers. Multiple-drug therapy is usually required, but not ACE inhibitors and ARBs. An ACE inhibitor or ARB is recommended first-line treatment for hypertension in patients with diabetes and urine albumin-to-creatinine ratio 300 mg/g creatinine. de Boer I, Bangalore S, Benetos A, et al. Diabetes and hypertension: A position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273-1284. doi:10.2337/dci17-0026. Continue reading >>

Ada Offers Position Statement On Diabetes And Hypertension

Ada Offers Position Statement On Diabetes And Hypertension

The American Diabetes Association (ADA) today offered a position statement on treating diabetes and hypertension for the first time since 2003. The American Diabetes Association (ADA) today offered a position statement on treating diabetes and hypertension for the first time since 2003. The statement incorporates findings from several key studies since that time, notably the 2010 ACCORD study (Action to Control Cardiovascular Risk in Diabetes). The statement, published in the journal Diabetes Care, features recommendations for diagnosing hypertension in patients with diabetes and an algorithm treating them, depending on how elevated their blood pressure is. The authors note that hypertension is a strong risk factor in atherosclerotic cardiovascular disease (ASCVD), heart failure, and microvascular complications that are the hallmarks of advanced diabetes, which contribute to both direct and indirect costs. In 2013, the ADA found that the annual costs of diabetes in the United States totaled $245 billion. Those with a blood pressure between 140/90 mm Hg and 160/100 mm Hg should start on a single antihypertensive agent, and those with a reading higher than 160/100 mg Hg should immediately start with 2 agents; both groups should improve their lifestyle management. The algorithm goes on to recommend specific agents depending on whether patients meet targets or experience adverse effects. The guideline continues the advice that most patients with diabetes should be treated to a blood pressure goal of <140/90 mm Hg; a goal of <130/80 can be considered for patients who have other cardiovascular risk factors. This follows results of ACCORD BP, which found no difference in a composite of cardiovascular events for patients whose blood pressure was treated to a much lower target o Continue reading >>

Ada Updates Guidelines For Patients With Hypertension, Diabetes

Ada Updates Guidelines For Patients With Hypertension, Diabetes

ADA Updates Guidelines for Patients With Hypertension, Diabetes Authors: News Author: Kristin Jenkins; CME Author: Charles P. Vega, MD Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s) ABIM Diplomates - maximum of 0.25 ABIM MOC points Nurses - 0.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology) Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs) This article is intended for primary care clinicians, endocrinologists, cardiologists, nurses, pharmacists, and other clinicians who treat and manage patients with diabetes. The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care. Upon completion of this activity, participants will be able to: Assess recommended interventions for patients with diabetes diagnosed with hypertension Distinguish antihypertensive drugs recommended for patients with diabetes As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content. Disclosure: Kristin Jenkins has disclosed no relevant financial relationships. Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships. Health Sciences Clinical Professo Continue reading >>

Ada Issues Updated Position Statement On Hypertension And Diabetes

Ada Issues Updated Position Statement On Hypertension And Diabetes

ACP Internist Weekly | Hypertension | August 29, 2017 ADA issues updated position statement on hypertension and diabetes The statement updates the ADA's 2003 position statement on this topic and summarizes clinical trials of intensive hypertension treatment strategies. The American Diabetes Association (ADA) issued an updated position statement last week on diagnosis and treatment of hypertension in patients with diabetes. The position statement, which updates the ADA's 2003 position statement on this topic, will appear in the September Diabetes Care and was published online on Aug. 22. It was developed by nine diabetes experts and summarizes clinical trials of intensive hypertension treatment strategies , such as the ACCORD BP (Action to Control Cardiovascular Risk in Diabetes-Blood Pressure) trial, the ADVANCEBP (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled EvaluationBlood Pressure) trial, the HOT (Hypertension Optimal Treatment) trial, and SPRINT (Systolic Blood Pressure Intervention Trial). The resulting recommendations include the following: Blood pressure should be measured at every routine clinical care visit in people with diabetes. If blood pressure is found to be 140/90 mm Hg or higher, it should be confirmed with multiple readings, including on a different day. The treatment goal for most patients with diabetes and hypertension should be below 140 mm Hg systolic and below 90 mm Hg diastolic. For patients at high risk for cardiovascular disease, lower targets, such as below 130/80 mm Hg, may be appropriate if they are achievable without undue treatment burden. For patients whose systolic blood pressure is above 120 mm Hg or diastolic blood pressure is above 80 mm Hg, lifestyle intervention should involve weight loss in those w Continue reading >>

More in diabetes